Company
Every investor coverage indicates participated in a round Johnson & Johnson raised.
Companies Johnson & Johnson acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Michael Grissinger | Vice President and Head, Worldwide Pharmaceutical Licensing (former) | OneVentures portfolio |
| Joaquín Duato | CEO | esade.edu |
| Elizabeth Cermak | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Johnson & Johnson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Atisama Therapeutics reports its Phase 1 trial of RB042 advancing into multiple ascending dose cohorts, and appoints experienced biopharma executive Bernard Coulie as chair of its board.
Profile of a Melbourne medtech firm making lifelike artificial organs that let surgeons rehearse robotic procedures, noting its 2023 capital raise, rapid growth, and leadership training through a Victorian scaleup program.
Esade honours the Klarna co-founder at its alumni day; he describes Norrsken's mission to support companies with positive impact and reflects on entrepreneurship, networking and mentoring.
Weekly roundup of eight Australian startups together securing $149 million: One Model, SafetyCulture, Hysata, Pendula, Marqo, Medigrowth, Curiious and Zena Sport, spanning HR analytics, safety tech, hydrogen, AI, medicinal cannabis, VR and sportstech.
Also Startup Daily·thebusinesstimes.com.au·Startup Daily·Startup Daily·SmartCompany·SmartCompany·Forbes Australia
Car subscription software firm Loopit hires Nima Idel to lead product growth, shortly after completing its first external capital raise of $3.6 million as it plans further expansion.
Antiviral nasal spray developer ENA Respiratory has joined the Blue Knight program run by JLABS and BARDA, the first Australian company selected; background notes recall its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.
Brandon Capital reports that ENA Respiratory has become the first Australian company chosen for BLUE KNIGHT, a JLABS-BARDA initiative supporting its intranasal broad-spectrum antiviral spray INNA-051.
Brisbane immunology company Kira Biotech has launched with a $20 million Series A, OneVentures leading alongside IP Group and Queensland government support, to progress its lead antibody KB312 into early human studies.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.
OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.